Extra sipuleucel-T after Provenge for prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether adding one extra infusion of sipuleucel-T (the same drug as Provenge) after the standard three doses can help men with advanced prostate cancer that no longer responds to hormone therapy. It is for men who have already finished their three Provenge infusions and have mild or no symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 or older
- You have advanced prostate cancer that is no longer controlled by hormone therapy (castrate-resistant)
- You have no or only mild symptoms from your cancer
- Your doctor has already prescribed and given you all 3 standard doses of Provenge
- You are not taking medications that weaken your immune system, like high-dose steroids or other immune-suppressing drugs
- You are expected to live at least another year
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding green tea extract and quercetin (a plant compound) to standard chemotherapy (docetaxel) can help men with advanced prostate cancer that has stopped responding to hormone therapy. The goal is to see if this combination is safe and works better than chemo alone.
This study combines an immunotherapy drug called sipuleucel-T (which boosts your immune system to fight cancer) with a high-dose testosterone treatment called bipolar androgen therapy. The goal is to see if this combination can help men with advanced prostate cancer that is not responding to usual hormone therapy.
This trial combines two immune-boosting treatments, Sipuleucel-T and N-803, to see if they can better fight prostate cancer that has spread and stopped responding to hormone therapy. It aims to help your immune system attack the cancer more effectively.
This trial tests a combination of two treatments for advanced prostate cancer that has stopped responding to hormone therapy. One treatment is a targeted radiation therapy (177Lu-PSMA-617) and the other is an immunotherapy (sipuleucel-T) that helps your immune system fight the cancer.
This trial tests a new combination of two drugs for men with advanced prostate cancer that has stopped responding to standard hormone therapy or chemotherapy. The goal is to see if this combination can help shrink tumors or slow the disease.
This early-phase study tests whether REGN4336 is safe and how well it works, by itself or with REGN5678, in adults with advanced prostate cancer. It may help people whose cancer has continued to worsen despite standard prostate cancer medicines.
Hear when a new Metastatic Castration-Resistant Prostate Cancer (mCRPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.